Navigation Links
Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
Date:10/20/2010

FREMONT, Calif., Oct. 20 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced it has dosed the first patient with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION) in its ongoing Phase I study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection.

The Phase I open-label, dose-escalation study was initiated during the first quarter of 2010 to evaluate the safety, tolerability and pharmacokinetic profile of QPI-1007 in patients with chronic nerve atrophy (Stratum I) and recent onset NAION (Stratum II). Enrollment has been completed, with no dose-limiting toxicities observed, in five of the six cohorts of Stratum I.  Dosing at the highest planned dose level has been initiated in this patient population. Up to 30 NAION patients will be enrolled in Stratum II. In addition to safety and pharmacokinetic assessments, changes in visual acuity and visual field following the administration of QPI-1007 will be measured.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "After escalating to the highest planned dose of QPI-1007 in patients with chronic nerve atrophy, we are excited to dose the first NAION patient in our ongoing clinical study of QPI-1007, which has demonstrated significant neuroprotective activity in preclinical studies."

About the Phase I Study

The Phase I, open-label, dose-escalation study will assess the safety, tolerability, and pharmacokinetic profile of QPI-1007 in patients with chronic nerve atrophy (Stratum I) and recent onset NAION (Stratum II).  The study is expected to enroll up to 66 patients to receive a single intravitreal injection of QPI-1007 at varying doses with assessments of safety and tolerability for 12 months post-injection.  Secondary outcome measures include describing any anatomical changes in the optic nerve h
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015 - ... agency ( http://www.epa.eu ) - Hitachi ... della nuova generazione di OASIS* all,ECR 2015. Si tratta ... alto campo da 1.2 T che migliora la capacità ... traguardo nell,attenzione al comfort del paziente. Le nuove funzionalità ...
(Date:3/5/2015)... DUBLIN and HAMPTON, N.J. ... (NYSE: MNK ), a leading global ... care company, announced today that they have entered into ... will acquire Ikaria, Inc. from a Madison Dearborn ... $2.3 billion. Subject to customary closing ...
(Date:3/5/2015)... , March 5, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, announced today that ... top rehabilitation hospitals for spinal cord injury and brain ... trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured ... injury (SCI). The Phase 1/2a trial ...
Breaking Medicine Technology:Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 2Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 3Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4
... 2011 In the quaint little town of Sierra Madre, ... as Microsoft and Oracle. By helping hospitals all over the ... Magazine,s "500" list of the nation,s fastest-growing companies. The ... They were ranked #1,190 just one year ago and are ...
... Corporation ("Unilife" or the "Company") (NASDAQ: UNIS ; ... Ramin Mojdeh, will purchase more than $250,000 in shares of ... initial open market purchase of more than $250,000 in Unilife ... Company. Dr. Mojdeh will begin making the purchase ...
Cached Medicine Technology:Small Town Company Thrives Against All Odds 2Small Town Company Thrives Against All Odds 3Unilife COO to Again Purchase More Than $250,000 in Company Shares 2Unilife COO to Again Purchase More Than $250,000 in Company Shares 3
(Date:3/5/2015)... York, New York (PRWEB) March 05, 2015 ... of men who allegedly suffered heart attacks, strokes and ... prescription low testosterone therapies continue to move forward in ... Court, Northern District of Illinois. According to a Case ... set forth procedures for the use of master pleadings ...
(Date:3/5/2015)... 2015 The Maricopa Community Colleges ... to the Arizona economy each year, according to a ... Economic Value of Maricopa County Community College District, summarizes ... district in fiscal year 2013-2014. , The analysis ... (EMSI), an organization that specializes in providing economic impact ...
(Date:3/5/2015)... Auburn, CA (PRWEB) March 05, 2015 ... and clinical solutions for the population health management arena, ... recently enhanced case management software, ACUITY Advanced Care™ (ACUITY) ... user interface, improved performance and the advantages of automation. ... 12:30 p.m. ET, will be led by Jeff Frater, ...
(Date:3/5/2015)... 05, 2015 Califia Farms , ... the natural products coffee drinks category[1], today unveils its ... West in Anaheim, Calif. Concentrated Cold Brew (CCB) ... Café, which democratizes the next wave of the coffee-taste ... need to become their own baristas. , Califia ...
(Date:3/5/2015)... March 05, 2015 For PASCHA Chocolate, ... most essential ingredients, the robust flavor of the cacao ... PASCHA Chocolate is free from peanuts, nuts, dairy, ... PASCHA's offering March 6th- 8th at Expo West., ... PASCHA Chocolate has broken new ground with their New ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 2Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 3Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:PASCHA Allergen Free Organic Chocolate to Appear at Natural Products Expo West March 6-8, 2015 2
... sign of severe asthma, which means that healthcare professionals ... complaints. Furthermore, more severe asthma appears to be more ... Sahlgrenska Academy,s Krefting Research Centre. Published in the ... study included 30,000 randomly selected participants from the west ...
... Biochemical Engineering Conference is the premier venue for unveiling ... The primary goal of this international conference has always ... engineers from diverse backgrounds to share insights on how ... engineering. As it enters its fourth decade, BME XVII ...
... HealthDay Reporter , MONDAY, Dec. 20 (HealthDay News) -- ... study finds that infants breast-fed for six months or longer, ... compared to bottle-fed tots, according to a new study. ... its positive benefits," said study leader Wendy Oddy, a researcher ...
... Ellin Holohan HealthDay Reporter , FRIDAY, Dec. 17 ... better known as heartburn, is not much of a risk ... research. "It,s a rare cancer," said study author ... of Michigan department of internal medicine. "About 1 in ...
... Dec. 20 (HealthDay News) -- ,Tis the season to be jolly, ... to take care of yourself during the holiday rush. While ... other tasks associated with the season, you need to take steps ... health, said Dr. Gary Kaplan, founder of the Kaplan Center for ...
... , SATURDAY, Dec. 18 (HealthDay News) -- The ... for people with chronic pain or other persistent health conditions ... them at risk for missed doses and even medication errors, ... advance planning can ensure safe and effective medication use over ...
Cached Medicine News:Health News:Nasal congestion can mean severe asthma 2Health News:Biochemical and Molecular Engineering XVII Conference 2Health News:Biochemical and Molecular Engineering XVII Conference 3Health News:Do Breast-Fed Baby Boys Grow Into Better Students? 2Health News:Do Breast-Fed Baby Boys Grow Into Better Students? 3Health News:For Most, Chronic Heartburn Not a Big Risk for Esophageal Cancer 2Health News:For Most, Chronic Heartburn Not a Big Risk for Esophageal Cancer 3Health News:Hectic Holiday Pace Can Upset Medication Schedule 2
... designed to travel a full 120 degrees, from ... wherever you release the rotating hand grip locking ... the handle with no need to ever go ... of system was designed to mimic the natural ...
Designed for Bariatric usage. Prevents arm or leg dropout during surgical procedures. Dimensions are 16"Lx10"H come in pairs. Optional gel pad available (BD2245)...
Designed to prevent arm or legs from dropouts during surgical procedures. Dimensions are 8"H x16"L. These come as pairs. Optional gel pads(BD2245)....
... Corporation offers a quality line ... to adults. Armboard covers are ... assuring easy cleaning while reducing ... Choose from three options: Disposable ...
Medicine Products: